Miller Anestesia

18. Schenone M, Furie BC, Furie B: The blood coagula-

tion cascade. Curr Opin Hematol 11:272–277, 2004.

19. Mann KG, Brummel-Ziedins K, Orfeo T, Butenas S:

Models of blood coagulation. Blood Cells Mol Dis

36:108–117, 2006.

20. Gomez K, McVey JH: Tissue factor initiated blood

coagulation. Front Biosci 11:1349–1359, 2006.

21. Eilertsen KE, Osterud B: Tissue factor: (patho)physio-

logy and cellular biology. Blood Coagul Fibrinolysis

15:521–538, 2004.

22. Gailani D, Renne T: The intrinsic pathway of coagu-

lation: A target for treating thromboembolic disease?

J Thromb Haemost 5:1106–1112, 2007.

23. Hoffman M: A cell-based model of coagulation and

the role of factor VIIa. Blood Rev 17(Suppl 1)S1–S5,

2003.

24. Esmon CT: Crosstalk between inflammation and

thrombosis. Maturitas 47:305–314, 2004.

25. Furie B, Furie BC: In vivo thrombus formation. J

Thromb Haemost 5(Suppl 1)12–17, 2007.

26. Mosesson MW: Fibrinogen and fibrin structure and

functions. J Thromb Haemost 3:1894–1904, 2005.

27. Crawley JT, Zanardelli S, Chion CK, Lane DA: The

central role of thrombin in hemostasis. J Thromb

Haemost 5(Suppl 1)95–101, 2007.

28. Barshtein G, Ben-Ami R, Yedgar S: Role of red blood

cell flow behavior in hemodynamics and hemostasis.

Expert Rev Cardiovasc Ther 5:743–752, 2007.

29. Medcalf RL: Fibrinolysis, inflammation, and regula-

tion of the plasminogen activating system. J Thromb

Haemost 5(Suppl 1)132–142, 2007.

30. Cesarman-Maus G, Hajjar KA: Molecular mechanisms

of fibrinolysis. Br J Haematol 129:307–321, 2005.

31. Andrews RK, Karunakaran D, Gardiner EE, Berndt

MC: Platelet receptor proteolysis: A mechanism for

downregulatingplateletreactivity.ArteriosclerThromb

Vasc Biol 27:1511–1520, 2007.

32. Shirk RA, Vlasuk GP: Inhibitors of factor VIIa/tissue

factor. Arterioscler Thromb Vasc Biol 27:1895–1900,

2007.

33. Wu KK, Matijevic-Aleksic N: Thrombomodulin: A

linker of coagulation and fibrinolysis and predictor of

risk of arterial thrombosis. Ann Med 32(Suppl 1)

73–77, 2000.

34. Maclean PS, Tait RC: Hereditary and acquired anti-

thrombin deficiency: Epidemiology, pathogenesis and

treatment options. Drugs 67:1429–1440, 2007.

35. Billett HH: Direct and indirect antithrombins: Hepa-

rins, low molecular weight heparins, heparinoids, and

hirudin. Clin Geriatr Med 17:15–29, 2001.

36. Kitchens CS: To bleed or not to bleed? Is that the

question for the PTT? J Thromb Haemost 3:2607–

2611, 2005.

37. Greaves M, Watson HG: Approach to the diagnosis

and management of mild bleeding disorders. J

Thromb Haemost 5(Suppl 1)167–174, 2007.

38. Sadler JE: New concepts in von Willebrand disease.

Annu Rev Med 56:173–191, 2005.

39. Lippi G, Franchini M, Guidi GC: Diagnostic approach

to inherited bleeding disorders. Clin Chem Lab Med

45:2–12, 2007.

40. Ruggeri ZM: The role of von Willebrand factor in

thrombus formation. Thromb Res 120(Suppl 1)S5–S9,

2007.

41. Slaughter TF, Parker JK, Greenberg CS: A rapid

method for the diagnosis of von Willebrand’s disease

subtypes by the clinical laboratory. Arch Pathol Lab

Med 119:148–152, 1995.

42. Harrison P: The role of PFA-100 testing in the inves-

tigation and management of haemostatic defects in

children and adults. Br J Haematol 130:3–10, 2005.

43. Franchini M: The use of desmopressin as a hemostatic

agent: A concise review. Am J Hematol 82:731–735,

2007.

44. Key NS, Negrier C: Coagulation factor concentrates:

Past, present, and future. Lancet 370:439–448, 2007.

45. Klinge J, Ananyeva NM, Hauser CA, Saenko EL:

Hemophilia A—from basic science to clinical prac-

tice. Semin Thromb Hemost 28:309–322, 2002.

46. Pierce GF, Lillicrap D, Pipe SW, Vandendriessche T:

Gene therapy, bioengineered clotting factors and novel

technologies for hemophilia treatment. J Thromb

Haemost 5:901–906, 2007.

47. Dargaud Y, Negrier C: Haemophilia therapies. Expert

Opin Biol Ther 7:651–663, 2007.

48. Duvall WL: Antithrombotic therapy. Curr Mol Med

6:603–619, 2006.

49. Roberts HR, Monroe DM, Escobar MA: Current con-

cepts of hemostasis: implications for therapy. Anes-

thesiology 100:722–730, 2004.

50. Meadows TA, Bhatt DL: Clinical aspects of platelet

inhibitors and thrombus formation. Circ Res

100:1261–1275, 2007.

51. Troxler M, Dickinson K, Homer-Vanniasinkam S:

Platelet function and antiplatelet therapy. Br J Surg

94:674–682, 2007.

52. Born G, Patrono C: Antiplatelet drugs. Br J Pharmacol

147(Suppl 1)S241–S251, 2006.

53. Goldhaber SZ, Turpie AG: Prevention of venous

thromboembolism among hospitalized medical

patients. Circulation 111:e1–e3, 2005.

54. Despotis GJ, Gravlee G, Filos K, Levy J: Anticoagula-

tion monitoring during cardiac surgery: A review of

current and emerging techniques. Anesthesiology

91:1122–1151, 1999.

55. Jobes DR: Safety issues in heparin and protamine

administration for extracorporeal circulation. J Car-

diothorac Vasc Anesth 12:17–20, 1998.

56. Nutescu EA, Wittkowsky AK, Dobesh PP, et al:

Choosing the appropriate antithrombotic agent

for the prevention and treatment of VTE: A case-

based approach. Ann Pharmacother 40:1558–1571,

2006.

57. Schulman S, Bijsterveld NR: Anticoagulants and their

reversal. Transfus Med Rev 21:37–48, 2007.

58. Dentali F, AgenoW, Crowther M: Treatment of couma-

rin-associated coagulopathy: A systematic review and

proposed treatment algorithms. J Thromb Haemost

4:1853–1863, 2006.

59. Baker RI, Coughlin PB, Gallus AS, et al: Warfarin

reversal: consensus guidelines, on behalf of the Aus-

tralasian Society of Thrombosis and Haemostasis.

Med J Aust 181:492–497, 2004.

60. Kujovich JL: Hemostatic defects in end stage liver

disease. Crit Care Clin 21:563–587, 2005.

61. Kaw D, Malhotra D: Platelet dysfunction and end-

stage renal disease. Semin Dial 19:317–322, 2006.

62. F

ranchiniM:Pathophysiology,

diagnosisandtreatment

of disseminated intravascular coagulation: An update.

Clin Lab 51:633–639, 2005.

63. Bick RL: Disseminated intravascular coagulation: A

review of etiology, pathophysiology, diagnosis, and

management: Guidelines for care. Clin Appl Thromb

Hemost 8:1–31, 2002.

64. Ageno W, Squizzato A, Garcia D, Imberti D: Epide-

miology and risk factors of venous thromboembo-

lism. Semin Thromb Hemost 32:651–658, 2006.

65. White RH: The epidemiology of venous thromboem-

bolism. Circulation 107:I4–I8, 2003.

66. Christiansen SC, Cannegieter SC, Koster T, et al:

Thrombophilia, clinical factors, and recurrent venous

thrombotic events. JAMA 293:2352–2361, 2005.

67. Simioni P: Who should be tested for thrombophilia?

Curr Opin Hematol 13:337–343, 2006.

68. Wu O, Robertson L, Twaddle S, et al: Screening for

thrombophilia in high-risk situations: Systematic

reviewandcost-effectivenessanalysis.TheThrombosis:

Risk and Economic Assessment of Thrombophilia

Screening (TREATS) study. Health Technol Assess

10:1–110, 2006.

69. Franchini M, Veneri D, Salvagno GL, et al: Inherited

thrombophilia. Crit Rev Clin Lab Sci 43:249–290,

2006.

70. Cooper PC, Rezende SM: An overview of methods for

detection of factor V Leiden and the prothrombin

G20210A mutations. Int J Lab Hematol 29:153–162,

2007.

71. Tripodi A: A review of the clinical and diagnostic

utility of laboratory tests for the detection of conge-

nital thrombophilia. Semin Thromb Hemost 31:

25–32, 2005.

72. Giannakopoulos B, Passam F, Rahgozar S, Krilis SA:

Current concepts on the pathogenesis of the anti-

phospholipid syndrome. Blood 109:422–430, 2007.

73. Ortel TL: The antiphospholipid syndrome: What are we

really measuring? How do we measure it? And how do

we treat it? J Thromb Thrombolysis 21:79–83, 2006.

74. Greinacher A, Warkentin TE: Recognition, treatment,

and prevention of heparin-induced thrombocytope-

nia: Review and update. Thromb Res 118:165–176,

2006.

75. Warkentin TE: HIT: Lessons learned. Pathophysiol

Haemost Thromb 35:50–57, 2006.

76. Bennett-Guerrero E, Slaughter TF, White WD, et al:

Preoperative anti-PF4/heparin antibody level predicts

adverse outcome after cardiac surgery. J Thorac Car-

diovasc Surg 130:1567–1572, 2005.

77. Stribling WK, Slaughter TF, Houle TT, Sane DC:

Beyond the platelet count: heparin antibodies as inde-

pendent risk predictors. Am Heart J 153:900–906,

2007.

78. Bates SM, Weitz JI: The status of new anticoagulants.

Br J Haematol 134:3–19, 2006.

79. Martin ME, Kloecker GH, Laber DA: Argatroban for

anticoagulation during cardiac surgery. Eur J Haema-

tol 78:161–166, 2007.

80. Sie P, Steib A: Central laboratory and point of care

assessmentofperioperativehemostasis.CanJAnaesth

53:S12–S20, 2006.

81. Kamal AH, Tefferi A, Pruthi RK: How to interpret and

pursue an abnormal prothrombin time, activated

partial thromboplastin time, and bleeding time in

adults. Mayo Clin Proc 82:864–873, 2007.

82. Peterson P, Hayes TE, Arkin CF, et al: The preoperative

bleeding time test lacks clinical benefit: College of

American Pathologists’ and American Society of

Clinical Pathologists’ position article. Arch Surg 133:

134–139, 1998.

83. Despotis GJ, Joist JH, Goodnough LT: Monitoring of

hemostasis in cardiac surgical patients: impact of

point-of-care testing on blood loss and transfusion

outcomes. Clin Chem 43:1684–1696, 1997.

84. Rochon AG, Shore-Lesserson L: Coagulation monito-

ring. Anesthesiol Clin 24:839–856, 2006.

85. Luddington RJ: Thrombelastography/thromboelasto-

metry. Clin Lab Haematol 27:81–90, 2005.

86. Di Benedetto P, Baciarello M, Cabetti L, et al: Throm-

belastography: Present and future perspectives in

clinicalpractice.MinAnestesiol69:501–509,509–515,

2003.

87. Matzdorff A: Platelet function tests and flow cytome-

try to monitor antiplatelet therapy. Semin Thromb

Hemost 31:393–399, 2005.

88. Michelson AD, Frelinger AL 3rd, FurmanMI: Current

options in platelet function testing. Am J Cardiol

98:4N–10N, 2006.

89. Peerschke EI: The laboratory evaluation of platelet

dysfunction. Clin Lab Med 22:405–420, 2002.

90. Hayward CP, Harrison P, Cattaneo M, et al: Platelet

function analyzer (PFA)-100 closure time in the eva-

luation of platelet disorders and platelet function.

J Thromb Haemost 4:312–319, 2006.

Coagulación

1545

Sección III

Control de la anestesia